- Home
- SNCY vs SLDB Comparison
SNCY vs SLDB Comparison
Compare SNCY & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- SLDB
- Stock Information
- Founded
- SNCY 1982
- SLDB 2013
- Country
- SNCY United States
- SLDB United States
- Employees
- SNCY N/A
- SLDB N/A
- Industry
- SNCY Air Freight/Delivery Services
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNCY Consumer Discretionary
- SLDB Health Care
- Exchange
- SNCY Nasdaq
- SLDB Nasdaq
- Market Cap
- SNCY 549.7M
- SLDB 529.4M
- IPO Year
- SNCY 2021
- SLDB 2018
- Fundamental
- Price
- SNCY $12.63
- SLDB $5.93
- Analyst Decision
- SNCY Buy
- SLDB Strong Buy
- Analyst Count
- SNCY 7
- SLDB 10
- Target Price
- SNCY $17.00
- SLDB $15.00
- AVG Volume (30 Days)
- SNCY 1.0M
- SLDB 1.1M
- Earning Date
- SNCY 07-31-2025
- SLDB 08-12-2025
- Dividend Yield
- SNCY N/A
- SLDB N/A
- EPS Growth
- SNCY 20.75
- SLDB N/A
- EPS
- SNCY 1.07
- SLDB N/A
- Revenue
- SNCY $1,100,145,000.00
- SLDB N/A
- Revenue This Year
- SNCY $5.51
- SLDB N/A
- Revenue Next Year
- SNCY $11.19
- SLDB N/A
- P/E Ratio
- SNCY $11.81
- SLDB N/A
- Revenue Growth
- SNCY 3.76
- SLDB N/A
- 52 Week Low
- SNCY $8.10
- SLDB $2.41
- 52 Week High
- SNCY $18.59
- SLDB $10.11
- Technical
- Relative Strength Index (RSI)
- SNCY 57.61
- SLDB 47.64
- Support Level
- SNCY $11.50
- SLDB $5.46
- Resistance Level
- SNCY $12.55
- SLDB $6.28
- Average True Range (ATR)
- SNCY 0.57
- SLDB 0.40
- MACD
- SNCY 0.10
- SLDB -0.14
- Stochastic Oscillator
- SNCY 86.76
- SLDB 32.32
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.